Out with the old, in with the new: Immunosuppression minimization in children

Current Opinion in Organ Transplantation

Volumn 13, Issue 5, 2008, Pages 513-521

  Sarwal, Minnie M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcineurin inhibitors; Corticosteroids; Immunosuppression minimization; Pediatric; Renal; Transplantation

Indexed keywords

ABATACEPT; ACICLOVIR; ALEMTUZUMAB; ANTILIPEMIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; GANCICLOVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; CALCINEURIN; DRUG DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ACNE; ACUTE GRAFT REJECTION; ARTERY DISEASE; AVASCULAR NECROSIS; BONE MARROW DISEASE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CHRONIC GRAFT REJECTION; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CUSHINGOID SYNDROME; DEFORMITY; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FIBROGENESIS; FRACTURE; GASTROINTESTINAL TOXICITY; GROWTH RETARDATION; HEART TRANSPLANTATION; HOMEOSTASIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MORBIDITY; MYOPATHY; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; REVIEW; SIDE EFFECT; VIRUS INFECTION; WOUND HEALING IMPAIRMENT; ADOLESCENT; CHILD; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; INFANT; KIDNEY TRANSPLANTATION; METABOLISM; NEWBORN; PRESCHOOL CHILD; RISK ASSESSMENT; TIME;

ADOLESCENT; CALCINEURIN; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; KIDNEY TRANSPLANTATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RISK ASSESSMENT; SIROLIMUS; STEROIDS; TIME FACTORS;

EID: 60849120819     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328310b0e0     Document Type: Review

References (54)

1. NAPRTCS. NAPRTCS 2006 annual report. 2006. https://web.emmes.com/ study/ped/annlrept/annlrept2006.pdf.
2. Banasik M, Klinger M. Chronic allograft nephropathy: immunologic and nonimmunologic factors. Ann Transplant 2006; 11:7-10.
3. Fortuna RS, Chinnock RE, Bailey LL. Heart transplantation among 233 infants during the first six months of life: the Loma Linda experience. Loma Linda Pediatric Heart Transplant Group. In: Cecka J, Terasaki RI, editors. Clin Transplants 1999, 15th in a series. Los Angeles, California: UCLA Immunogenetics Center; 2000. pp. 263-272.
4. West LJ. Crossing the ABO barrier in infant heart transplantation at the Hospital for Sick Children. In: Cecka J, Terasaki RI, editors. Clin Transplants 2004, 20th in a series. Los Angeles, California: UCLA Immunogenetics Center; 2005. pp. 243-252.
5. Sarwal MM, Cecka JM, Millan MT, Salvatierra O Jr. Adult-size kidneys without acute tubular necrosis provide exceedingly superior long-term graft outcomes for infants and small children: a single center and UNOS analysis. United Network for Organ Sharing. Transplantation 2000; 70:1728-1736.
6. Kamada N, Brons G, Davies HS. Fully allogenic liver grafting in rats induces a state of systemic nonreactivity to donor transplantation antigens. Transplantation 1980; 29:429-431.
7. Sumimoto R, Kamada N. Specific suppression of allograft rejection by soluble class I antigen and complexes with monoclonal antibody. Transplantation 1990; 50:678-682.
8. Thomson AW, Lu L, Wan Y, et al. Identification of donor-derived dendritic cell progenitors in bone marrow of spontaneously tolerant liver allograft recipients. Transplantation 1995; 60:1555-1559.
9. Starzl TE, Murase N, Thomson AW, et al. Regulation of immune reactivity and tolerance by antigen migration and localization: with particular reference to allo- and xenotransplantation. Transplant Proc 1999; 31:1806-1811.
10. Starzl TE, Murase N, Thomson AW, et al. Immunity and tolerance are related, and governed by antigen migration and localization. Transplant Proc 1999; 31:1406-1411.
11. Kingston RW, Goldsmith DJ. Chronic renal allograft dysfunction: the evidence for a change in immunosuppression. Minerva Urol Nefrol 2006; 58:23-28.
12. Alexander SI, Fletcher JT, Nankivell B. Chronic allograft nephropathy in paediatric renal transplantation. Pediatr Nephrol 2007; 22:17-23.
13. Brook NR, Waller JR, Bicknell GR, Nicholson ML. The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model. Transplant Proc 2005; 37:130-133.
14. Sarwal MM, Yorgin PD, Alexander S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001; 72:13-21.
15. Veenstra DL, Best JH, Hornberger J, et al. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33:829-839.
16. Balfour IC, Srun SW, Wood EG, et al. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients. J Heart Lung Transplant 2006; 25:518-522.
17. Bererhi L, Flamant M, Martinez F, et al. Rapamycin-induced oligospermia. Transplantation 2003; 76:885-886.
18. YiT, Cuchara L, Wang Y, et al. Human allograft arterial injury is ameliorated by sirolimus and cyclosporine and correlates with suppression of interferongamma. Transplantation 2006; 81:559-566.
19. Jimenez-Rivera C, Avitzur Y, Fecteau AH, et al. Sirolimus for pediatric liver transplant recipients with posttransplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant 2004; 8:243-248.
20. Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005; 5:1748-1756.
21. Land W, Vincenti F. Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation 2005; 80:S221-S234.
22. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67:1036-1042.
23. Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1 H as induction therapy in renal transplantation: preliminary results. Transplantation 2004; 78:426-433.
24. Vincenti F, Ramos E, Brattstrom C, et al. Multicentertrial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282-1287.
25. Bestard O, Cruzado JM, Grinyo JM. Calcineurin-inhibitor-sparing immunosuppressive protocols. Transplant Proc 2005; 37:3729-3732.
26. Harmon W, Meyers K, Ingelfinger J, et al. Safety and efficacy of a calcineurin inhibitor avoidance regimen in pediatric renal transplantation. J Am Soc Nephrol 2006; 17:1735-1745.
27. Weintraub L, Li L, Alexander S, Sarwal M. Calcineurin inhibitor withdrawal in children: step with care. Transplantation 2006; 82:287.
28. McDonald R, Smith J, Meyers K, et al. A Phase II exploratory study to evaluate the safety of induction therapy with Campath-1H, combined with chronic immunosuppression with MMF and Sirolimus: a study of the cooperative clinical trials in Pediatric Transplantation. In: American Transplant Congress, Toronto, Canada, 2008.
29. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353:770-781.
30. Woodle ES, Vincenti F, Lorber MI, et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant 2005; 5:157-166.
31. Washburn K, Speeg KV, Esterl R, et al. Steroid elimination 24 h after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation 2001; 72:1675-1679.
32. Jordan ML, Chakrabarti P, Luke P, et al. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. Transplantation 2000; 69:265-271.
33. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79:807-814.
34. Boillot O, Mayer DA, Boudjema K, et al. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl 2005; 1:61-67.
35. Sarwal MM, Benfield M, Ettenger R, et al. One year results of a prospective, randomized, multicenter trial of steroid avoidance in pediatric renal transplantation. In: American Transplant Congress, Toronto, Canada, 2008.
36. Li L, Chaudhuri A, Weintraub L, et al. Sub-clinical CMV and EBV viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 2007; 11:187-195.
37. Hocker B, John U, Plank C, et al. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years. Transplantation 2004; 78:228-234.
38. Motoyama O, Hasegawa A, Ohara T, et al. A prospective trial of steroid withdrawal after renal transplantation treated with cyclosporine and mizoribine in children: results obtained between 1990 and 2003. Pediatr Transplant 2005; 9:232-238.
39. Sarwal M, Pascual J. Immunosuppression minimization in pediatric transplantation. Am J Transplant 2007; 7:2227-2235.
40. Cole E, Landsberg D, Russell D, et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001; 72:845-850.
41. Boardman RE, Alloway RR, Alexander JW, et al. African-American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression. Am J Transplant 2005; 5:356-365.
42. Alloway RR, Hanaway MJ, Trofe J, et al. A prospective, pilot study of early corticosteroid cessation in high-immunologic-risk patients: the Cincinnati experience. Transplant Proc 2005; 37:802-803.
43. Matas AJ, Kandaswamy R, Humar A, et al. Long-term immunosuppression, without maintenance prednisone, after kidney transplantation. Ann Surg 2004; 240:510-526; discussion 6-7.
44. Stratta RJ, Alloway RR, Hodge E, Lo A. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. Clin Transplant 2002; 16:60-68.
45. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005; 200:505-515; quiz A59-A61.
46. Parrott NR, Hammad AQ, Watson CJ, et al. Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients. Transplantation 2005; 79:344-348.
47. Lim WK, Ursea R, Rao K, et al. Bilateral uveitis in a patient with autoimmune lymphoproliferative syndrome. Am J Ophthalmol 2005; 139:562-563.
48. McCauley J. Steroid-free lymphocyte depletion protocols. The potential for partial tolerance? Contrib Nephrol 2005; 146:43-53.
49. Pirenne J, Kawai M. Tolerogenic protocol for intestinal transplantation. Transplant Proc 2006; 38:1664-1667.
50. Satterwhite T, Chua MS, Hsieh SC, et al. Increased expression of cytotoxic effector molecules: different interpretations for steroid-based and steroid-free immunosuppression. Pediatr Transplant 2003; 7:53-58.
51. Kim JS, Aviles DH, Silverstein DM, et al. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 2005; 9:162-169.
52. Vehaskari VM. Treatment practices of FSGS among North American pediatric nephrologists. Pediatr Nephrol 1999; 13:301-303.
53. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002; 62:1060-1067.
54. Schachter AD, Meyers KE, Spaneas LD, et al. Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. Pediatr Transplant 2004; 8:171-177.